PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Variant-Stratified ALK Inhibitor Selection in EML4-ALK Lung Cancer

This narrative review synthesizes EML4-ALK variant biology, resistance mechanisms, and a proposed risk-stratified treatment algorithm that oncology pharmacists can apply to inhibitor selection and monitoring.
crizotinibalectinibbrigatinibceritiniblorlatinibiruplinalkibALK inhibitorsALK-TKIEML4-ALKNSCLCprotein degradersPROTACctDNAliquid biopsynarrative reviewprecision oncology Oncology Pharmacy

Background Information

EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.

EML4-ALK fusion in NSCLC represents a significant target for precision oncology, where targeted therapies can enhance patient outcomes. ALK inhibitors are effective against EML4-ALK mutations; however, drug resistance limits long-term success. Continuous tumor monitoring and adaptive treatment strategies are crucial to manage resistance and optimize treatment in EML4-ALK-positive NSCLC. Effective management of EML4-ALK-positive NSCLC requires vigilant monitoring and adaptive therapy strategies due to drug resistance.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Li S, Bao L, Zhou D, Li D

Citation: Li S, Bao L, Zhou D, et al. EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies. Technology in cancer research & treatment. 2026;25:15330338261457490. doi:10.1177/15330338261457490

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →